Table 1.
N(%) | BE | E | Total |
---|---|---|---|
Full Analysis Set | 112 | 112 | 224 |
P0 | 108 (96.4) | 107 (95.5) | 215 (96.0) |
P1 | 95 (84.8) | 97(86.6) | 192 (85.7) |
P2 | 42 (37.5) | 53 (47.3) | 95 (42.4) |
P3 | 25 (22.3) | 36 (32.1) | 61 (27.2) |
P4 | 19 (17.0) | 15 (13.4) | 34 (15.2) |
T0 | 2 (1.8) | 3 (2.7) | 5 (2.2) |
T1 | 7 (6.3) | 9 (8.0) | 16 (7.1) |
T2 | 3 (2.7) | 3 (2.7) | 6 (2.7) |
Plasma samples, P0: Before the start of study treatment, P1: 6 weeks from the start of study treatment, P2: At the time of definite disease progression during initial treatment, P3: 6 weeks from the start of second-line treatment, and P4: At the time of definite disease progression during second-line treatment. Tissue samples were not mandatory, T0: Before the start of study treatment, T1: At the time of definite disease progression during initial treatment and T2: At the time of definite disease progression during second-line treatment.